Joerg Moeller, Md, Phd Email and Phone Number
Joerg Moeller, MD, PhD, is a Member of the Board of Directors at Secura Bio Holdings, Inc., an integrated, commercial-stage pharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients. Previously, he was the Chief Executive Officer and Executive Board member of BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery. As the former Head of Global Research and Development at Bayer Pharmaceuticals and a member of Bayer Pharma´s Executive Committee, he has successfully led large organizations in research, development, and regulatory compliance and built growth portfolios through productive and collaborative partnerships with academic institutions, biotech companies, and pharmaceutical peers. He is passionate about fostering a culture of excellence, innovation, and diversity in his teams and across the industry. He is also an advocate of digitalization and artificial intelligence as drivers of R&D efficiency and quality. Joerg Moeller was the former Corporate Executive Vice President and Head of Global Research and Development (R&D) at LEO Pharma, a leading dermatology company.With over 30 years of experience in the pharmaceutical industry, Joerg Moeller has a proven track record of developing to successful approval innovative and competitive drugs in various therapeutic areas, such as cardiovascular, oncology, hematology, ophthalmology, dermatology, womens´health, and infectious diseases incl. a number of first-in class medicines that obtained blockbuster status.
Antag Therapeutics
View- Website:
- antagtherapeutics.com
- Employees:
- 19
-
Chief Executive OfficerAntag TherapeuticsCopenhagen, Dk
-
Member Of The Board Of Directors, Non-Executive DirectorSecura Bio, Inc. Dec 2023 - PresentVereinigte Staaten Von Amerika -
Ceo And Executive DirectorBenevolentai Jan 2024 - Dec 2024London, England, Vereinigtes KönigreichCEO of BenevolentAI, a leader in applying advanced AI to accelerate biopharma drug discovery. -
Corporate Evp, Head Of Global Research And DevelopmentLeo Pharma Jan 2021 - Nov 2023Copenhagen, Capital Region, Denmark -
Member Of The Board Of DirectorsBluerock Therapeutics Oct 2019 - Dec 2020Greater Boston Area -
Corporate Evp, Head Of Global R&D And Member Of The Pharmaceuticals Executive Committee At Bayer AgBayer Jan 2018 - Dec 2020Düsseldorf Area, GermanyStrategic executive with deep, broad-based expertise in development and outstanding track record of achievement in clinical development leading to regulatory approval of first in-class and best in-class mechanisms• reporting to CEO and President of Bayer AG's Pharmaceuticals Division• responsible for planning and execution of all global research and development activities across the whole portfolio of Bayer Pharmaceuticals (Cardiology and Hematology, Oncology Research, Ophthalmology, Womens Health and Primary Care)• track record includes development to approval of Moxifloxacin (Avelox), Vardenafil (Levitra), Sorafenib (Nexavar), Rivaroxaban (Xarelto), Regorafenib (Stivarga), Aflibercept (Eylea), Radium-223 (Xofigo), Riociguat (Adempas) and Copanlisib (Aliqopa).• leading a global organization of + 7.000 FTEs, Budget > 2.8 Bio. € annually• Respected, influential leader; a valued go-to resource trusted to provide insights to improve business-critical decision-making • Inspirational leader who is effective in motivating global teams to achieve challenging goals• Member, Board of Directors, Casebia Therapeutics, Cambridge, MA (USA)• Member, Board of Directors, BlueRock Therapeutics, Cambridge, MA (USA)Specialties: Clinical development, new business development, leading, managing and motivating a global organization to achieve best in class performance -
Corporate Evp, Head Of Global Development And Member Of The Pharma Excecutive Committee At Bayer AgBayer Ag, Pharmaceuticals Division Feb 2014 - Dec 2017Düsseldorf Area, Germany• Head of Global Development and Member of the Executive Committee of Bayer AG's Pharmaceuticals Division reporting to the CEO and President of Bayer AG's Pharmaceuticals Division• responsible for phase II and phase III development to approval across the whole portfolio of Bayer HealthCare Pharmaceuticals (cardiovascular, oncology, ophthalmology, womens’ health, anti-infectives, kidney disease, dermatology)• global responsibility includes clinical development, clinical operations, regulatory affairs for pharmaceuticals and consumer health projects and products, R&D quality, portfolio management• leading a global organization of more than 2800 FTEs with main locations in Germany, US, Japan and China• annual budget responsibility of more than 1 bio. €
-
Corporate Senior Vice President, Head Of Global Clinical DevelopmentBayer Healthcare Pharmaceuticals Oct 2012 - Jan 2014Whippany, New Jersey (Usa)In addition to previous role, added responsibility for Global Clinical Operations and Global Data Management.Leading global clinical development function of about +1.100 permanent FTEs in company externally recognized as one of the fastest in drug development worldwide, engaged staff around shared goals – achieving several outstanding milestones.• reporting to Head of Global Development, Pharmaceuticals• Directed development of Xarelto© (Rivaroxaban) an oral direct FXa inhibitor, overseeing one of the largest and most complex development programs in the industry with 75,000 patients. In its first indication, Xarelto© was developed and approved in just 78 months.• Oversaw clinical development of Nexavar© (Sorafenib), the first new oncology drug to receive FDA approval for advanced renal cell carcinoma in over a decade. Completed clinical development in 6.3 years versus 10 year average for oncology drugs. Earned FDA approval in 5.4 months versus 14-month average.• Completed landmark study that led to approval of Nexavar© for hepatocellular carcinoma, the first drug ever to show prolongation of overall survival in patients.• track record includes development of Avelox, Levitra, Nexavar, Xarelto, Stivarga, Skyla, Xofigo and Riociguat
-
Corporate Svp, Head Of Global Clinical DevelopmentBayer Healthcare Nov 2007 - Sep 2012Düsseldorf Area, GermanyLeading clinical development in company externally recognized as one of the fastest in drug development worldwide, engaged staff around shared goals – achieving several outstanding milestones.• reporting to Head of Global Development, Pharmaceuticals• Directed development of Xarelto© (Rivaroxaban) an oral direct FXa inhibitor, overseeing one of the largest and most complex development programs in the industry with 75,000 patients. In its first indication, Xarelto© was developed and approved in just 78 months.• Oversaw clinical development of Nexavar© (Sorafenib), the first new oncology drug to receive FDA approval for advanced renal cell carcinoma in over a decade. Completed clinical development in 6.3 years versus 10 year average for oncology drugs. Earned FDA approval in 5.4 months versus 14-month average.• Completed landmark study that led to approval of Nexavar© for hepatocellular carcinoma, the first drug ever to show prolongation of overall survival in patients.• track record includes development of Avelox, Levitra, Nexavar, Xarelto, Stivarga, Skyla, Xofigo and Riociguat
-
Vp, Head Of Global Clinical DevelopmentBayer Healthcare Mar 2003 - Oct 2007Düsseldorf Area, Germany
-
Vp, Head Of Strategic Drug Development CardiovascularBayer Oct 2001 - Feb 2003Düsseldorf Area, Germany
-
Member Of The Board Of DirectorsCasebia Therapeutics Jan 2018 - Dec 2020Boston, Massachusetts, Vereinigte Staaten
Frequently Asked Questions about Joerg Moeller, Md, Phd
What company does Joerg Moeller, Md, Phd work for?
Joerg Moeller, Md, Phd works for Antag Therapeutics
What is Joerg Moeller, Md, Phd's role at the current company?
Joerg Moeller, Md, Phd's current role is Chief Executive Officer.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial